PVLA News & Events

Shares of Palvella Therapeutics are moving higher after the company this morning reported its Q4 results and provided a corporate update. The company's 2025 earnings per share is ($3.71), compared to ($7.83) in 2024 and the consensus estimate of ($3.52). Palvella's pro forma cash was $274M as of December 31, 2025. In March, the company submitted a pre-new drug application meeting request to the FDA, with a meeting anticipated in Q2. The company said it expanded the development of Qtorin rapamycin into "clinically significant" angiokeratomas. Shares of Palvella Therapeutics are up 11%, or $12.70, to $123.37 in morning trading.

Palvella Therapeutics "announced that the European Patent Office has issued European Patent No. 3565520, which includes claims covering QTORIN(TM) 3.9% rapamycin anhydrous gel , the Company's lead product candidate from the QTORIN(TM) platform. The patent provides protection for anhydrous topical compositions and methods of use for QTORIN(TM) rapamycin, including for the treatment of microcystic lymphatic malformations, venous malformations, and other diseases associated with dysregulation of the mammalian target of rapamycin (mTOR) pathway."